Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1654 1675
This examiner grants 63% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17785279 | STAPLED LACTAM CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS | Final Rejection | Merck Sharp & Dohme LLC |
| 17785287 | STAPLED TRIAZOLE CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS | Final Rejection | Merck Sharp & Dohme LLC |
| 18254166 | INJECTABLE BIODEGRADABLE POLYMERIC COMPLEX FOR GLUCOSE-RESPONSIVE INSULIN DELIVERY | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 17920698 | INHIBITION OF SARS-COV-2 VIRAL ENTRY THROUGH ORAL ADMINISTRATION OF LACTOFERRIN AND USES THEREOF | Non-Final OA | The Regents of the University of Michigan |
| 17504500 | GLP-1R AGONIST REDUCES RETINAL INFLAMMATION AND NEURON DEATH SECONDARY TO OCULAR HYPERTENSION | Final Rejection | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 17995017 | Peptide Having Mesenchymal Stem Cell Mobilizing Activity | Non-Final OA | OSAKA UNIVERSITY |
| 18037379 | TYROSYL-LOCK PEPTIDES | Non-Final OA | The University of Queensland |
| 17827584 | COMPOSITIONS AND METHODS FOR TREATING NERVOUS SYSTEM INJURIES | Final Rejection | Sanford Burnham Prebys Medical Discovery Institute |
| 18266159 | COMPOSITIONS AND METHODS FOR CONTROLLED OVARIAN STIMULATION | Non-Final OA | Ferring B.V. |
| 18173264 | VIRAL RECEPTOR-DERIVED PEPTIDES AGAINST VIRAL DISEASES | Final Rejection | Howard University |
| 17915976 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING MUCOSITIS INDUCED BY RADIOTHERAPY, CHEMOTHERAPY, OR COMBINATION THEREOF, COMPRISING GLP-2 DERIVATIVES OR LONG-ACTING CONJUGATE OF SAME | Non-Final OA | HANMI PHARM. CO., LTD. |
| 18012496 | LOW-DOSE PHARMACEUTICAL COMPOSITIONS OF GHRH ANALOGS AND USES THEREOF | Non-Final OA | Woodward Specialty LLC |
| 18053765 | LIQUID BANDAGE CONTAINING PEPTIDE ANTI-INFLAMMATORY ACTIVE INGREDIENTS AND PREPARATION METHOD THEREOF | Non-Final OA | ZHEJIANG OCEAN UNIVERSITY |
| 18279992 | POLYPEPTIDE AND POLYPEPTIDE COMPOSITION SPECIFICALLY BINDING TO SARS-COV-2 SPIKE PROTEIN, AND PREPARATION METHOD AND USE THEREOF | Non-Final OA | NATIONAL CENTER FOR NANOSCIENCE AND TECHNOLOGY |
| 18177387 | OPTIMIZED RATIOS OF AMINO ACIDS AND SUGARS AS AMORPHOUS STABILIZING COMPOUNDS IN PHARMACEUTICAL COMPOSITIONS CONTAINING HIGH CONCENTRATIONS OF PROTEIN-BASED THERAPEUTIC AGENTS | Final Rejection | MedImmune, LLC |
| 18116849 | COMPOSITION AND METHODS OF TREATMENT USING TRANSDERMAL HORMONE SUPPLEMENTATION | Final Rejection | Xygenyx Inc. |
| 18025266 | Medicine for Preventing or Treating Symptom or Disorder in Subject Affected by Viral Infection | Non-Final OA | University of Miyazaki |
| 18027872 | GLP-1R/GCGR Dual Target Agonist Polypeptide Derivative for Treatment of Hepatic Fibrosis Associated with Viral Hepatitis | Final Rejection | Shenzhen Turier Biotech. Co., Ltd. |
| 18042892 | METHOD FOR THE TREATMENT OF A DISEASE USING PIGMENT EPITHELIUM-DERIVED FACTOR (PEDF) | Non-Final OA | Curebiotech GmbH |
| 18079545 | Methods of Treating Cardiac Injury | Final Rejection | Proletariat Therapeutics, Inc. |
| 18009590 | C-Type Natriuretic Peptides and Methods Thereof in Treating Acute Lung Injury | Non-Final OA | PharmaIN Corporation |
| 17792787 | PEPTIDE COMPOUNDS AND METHODS OF TREATING DISEASES USING SAME | Non-Final OA | Immunity Pharma Ltd. |
| 17630258 | INSULIN ANALOGUES WITH GLUCOSE REGULATED CONFORMATIONAL SWITCH | Final Rejection | Thermalin Inc. |
| 17415474 | PHARMACEUTICAL COMPOSITION INCLUDING INSULIN AND GLUCAGON | Final Rejection | HANMl PHARM. CO., LTD |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy